Table Info

Table 2.

Clinical, hemodynamic, and biological parameters 48 h after RVAD implantation

Parameters	RVAD with Protek Duo^® cannula N = 8	Open t-RVAD N = 14	P-value
Hemodynamic data
MAP (mmHg)	63 ± 6	57 ± 5	0.05
CVP (mmHg)	17 ± 2	20 ± 7	0.09
Biological data
Creatinine (mg/dL)	1.29 ± 0.38	1.42 ± 0.74	0.61
Bilirubin (mg/dL)	9 ± 13	6 ± 4	0.75
AST (unit/L)	892 ± 815	346 ± 794	2.09
Lactate (mmol/L)	2.0 ± 0.4	4.8 ± 4.6	0.05
Platelets (k/uL)	180 ± 91	99 ± 40	0.049
Life supports
Use of NO	8 (100)	8 (57.1)	0.05
Requiring mechanical ventilation > 24 h	7 (87.5)	11 (78.6)	0.04
Use of renal replacement therapy	5 (62.5)	9 (64.3)	0.92
Epinephrine doses 24 h after the RVAD (mcg/kg/min)	0.05 ± 0.04	0.05 ± 0.06	0.85
Norepinephrine doses 24 h after the RVAD (mcg/kg/min)	0.02 ± 0.035	0.02 ± 0.035	0.82
Milrinone doses 24 h after the RVAD (mcg/kg/min)	0.23 ± 0.22	0.12 ± 0.19	0.21
Vasopressin doses 24 h after the RVAD (u/hour)	0.04 ± 0.037	0.29 ± 0.035	0.59

RVAD: right ventricular assist device; MAP: mean arterial pressure; CVP: central venous pressure; AST: aspartate aminotransferase; NO: nitric oxide; RVAD: right ventricular assist device. Statistically significant differences are bolded and highlighted

Declarations

Author contributions

AP: Writing—original draft. AK: Data curation. NA: Data curation, Formal Analysis. CB: Writing—original draft. BS: Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This study was approved by the institutional review board at Penn State Health: Study identification number: STUDY00012511.

Consent to participate

During the institutional review board (IRB) application, the need for consent was waived as there were no unique patient identifiers that would be used in the data of this project.

Consent to publication

Not applicable.

Availability of data and materials

The datasets generated in this study can be found with the corresponding author and the raw data can be available if requested.

Funding

Not applicable.

Copyright

References

Dang NC, Topkara VK, Mercando M, Kay J, Kruger KH, Aboodi MS, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant. 2006;25:1–6. [DOI] [PubMed]

Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163–72. [DOI] [PubMed] [PMC]

Patel ND, Weiss ES, Schaffer J, Ullrich SL, Rivard DC, Shah AS, et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. Ann Thorac Surg. 2008;86:832–40. [DOI] [PubMed]

Lampert BC, Teuteberg JJ. Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant. 2015;34:1123–30. [DOI] [PubMed]

Baumwol J, Macdonald PS, Keogh AM, Kotlyar E, Spratt P, Jansz P, et al. Right heart failure and “failure to thrive” after left ventricular assist device: clinical predictors and outcomes. J Heart Lung Transplant. 2011;30:888–95. [DOI] [PubMed]

Santambrogio L, Bianchi T, Fuardo M, Gazzoli F, Veronesi R, Braschi A, et al. Right ventricular failure after left ventricular assist device insertion: preoperative risk factors. Interact Cardiovasc Thorac Surg. 2006;5:379–82. [DOI] [PubMed]

Riebandt J, Haberl T, Wiedemann D, Moayedifar R, Schloeglhofer T, Mahr S, et al. Extracorporeal membrane oxygenation support for right ventricular failure after left ventricular assist device implantation. Eur J Cardiothorac Surg. 2018;53:590–5. [DOI] [PubMed]

Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al.; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32:157–87. [DOI] [PubMed]

Cheung AW, White CW, Davis MK, Freed DH. Short-term mechanical circulatory support for recovery from acute right ventricular failure: clinical outcomes. J Heart Lung Transplant. 2014;33:794–9. [DOI] [PubMed]

10.

Aggarwal V, Einhorn BN, Cohen HA. Current status of percutaneous right ventricular assist devices: First-in-man use of a novel dual lumen cannula. Catheter Cardiovasc Interv. 2016;88:390–6. [DOI] [PubMed]

11.

Bermudez CA, Lagazzi L, Crespo MM. Prolonged Support Using a Percutaneous OxyRVAD in a Patient with End-Stage Lung Disease, Pulmonary Hypertension, and Right Cardiac Failure. ASAIO J. 2016;62:e37–40. [DOI] [PubMed]

12.

Kazui T, Tran PL, Echeverria A, Jerman CF, Iwanski J, Kim SS, et al. Minimally invasive approach for percutaneous CentriMag right ventricular assist device support using a single PROTEKDuo Cannula. J Cardiothorac Surg. 2016;11:123. [DOI] [PubMed] [PMC]

13.

Leidenfrost J, Prasad S, Itoh A, Lawrance CP, Bell JM, Silvestry SC. Right ventricular assist device with membrane oxygenator support for right ventricular failure following implantable left ventricular assist device placement. Eur J Cardiothorac Surg. 2016;49:73–7. [DOI] [PubMed]

14.

Schmack B, Farag M, Kremer J, Grossekettler L, Brcic A, Raake PW, et al. Results of concomitant groin-free percutaneous temporary RVAD support using a centrifugal pump with a double-lumen jugular venous cannula in LVAD patients. J Thorac Dis. 2019;11:S913–20. [DOI] [PubMed] [PMC]

15.

Schmack B, Weymann A, Popov AF, Patil NP, Sabashnikov A, Kremer J, et al. Concurrent Left Ventricular Assist Device (LVAD) Implantation and Percutaneous Temporary RVAD Support via CardiacAssist Protek-Duo TandemHeart to Preempt Right Heart Failure. Med Sci Monit Basic Res. 2016;22:53–7. [DOI] [PubMed] [PMC]